The role of myostatin in alcohol and hypertensive heart diseases

Main Article Content

JOAQUIM FERNANDEZ-SOLA ANA PLANAVILA PORTA

Abstract

Myostatin (GDF-8) is a major regulatory factor on cardiac metabolism, function and energy homeostasis. Although the main site for myostatin expression is the skeletal muscle, it has a relevant role in heart pathophysiology. Myostatin up-regulation inhibits cardiac myocyte proliferation and protects the cell from apoptosis. Myostatin disruption induces myocyte hyperplasia, hypertrophy and proliferation, increasing global cardiac mass. Myostatin up-regulation appears after different pathological heart conditions such as ventricular hypertrophy and chronic heart failure.  

Alcohol misuse up-regulates myostatin cardiac expression, a fact similar to that happens in hypertension or other causes of cardiomyopathy (CMP). In the case of chronic alcoholics, this myostatin up-regulation is higher and the heart proliferation ratio lower compared to other groups with CMP.  In the presence of isolated hypertension myocardial myostatin activity is not modified, but in hypertensive CMP, heart myostatin expression is clearly increased.

The presence of structural dilated CMP induces a significant increase in heart myostatin expression independently of their etiology, either in alcoholic, hypertensive, valve, ischemic or idiopathic CMP.  In the setting of heart failure, myostatin expression is also up-regulated independently of their etiologic cause, especially in end-stage heart failure. Myostatin up-regulation probably appears to limit the compensatory but excessive cardiac growth. It contributes to restrict unhealthy repair mechanisms mostly myocyte hypertrophy and proliferation and also regulates heart energy homeostasis.

In addition to myostatin, other novel cardiomyokines such as IGF-1, FGF21 and Metrnl appear to have a relevant role in regulation of cardiac hypertrophy and remodelling. These cardiomyokines have also been proposed as diagnostic markers and potential therapeutic agents.

In alcohol and hypertensive heart diseases, in addition to decrease heart aggressive factors (alcohol intake, hypertension overload), control of local cardiac neuro-hormonal pathways will be relevant points to consider in the future. 

Article Details

How to Cite
FERNANDEZ-SOLA, JOAQUIM; PLANAVILA PORTA, ANA. The role of myostatin in alcohol and hypertensive heart diseases. Medical Research Archives, [S.l.], v. 4, n. 2, july 2016. ISSN 2375-1924. Available at: <https://esmed.org/MRA/mra/article/view/514>. Date accessed: 02 mar. 2024.
Keywords
MYOSTATIN, HEART, ALCOHOL, HYPERTENSION, CARDIOMYOPATHY, HEART HYPERTROPHY, CARDIOMYOKINES.
Section
Review Articles

References

Argilés, J.M., Orpí, M., Busquets, S., López-Soriano, F.J. (2012). Myostatin: more than just a regulator of muscle mass. Discov Today, 17(13-14),702-709. doi: 10.1016/j.drudis.2012.02.001. PMID: 22342983
Baán, J.A., Varga, Z.V., Leszek, P., Kuśmierczyk, M., Baranya,i T., Dux, L., Ferdinandy, P., Braun, T., Mendler, L.(2015). Myostatin and IGF-I signalling in end-stage human heart failure: a qRT-PCR study. J Transl Med, 13,1. doi: 10.1186/s12967-014-0365-0. PMID:25591711
Biesemann, N., Mendler, L., Wietelmann, A., Hermann, S., Schäfers, M., Krüger, M., Boettger, T., Borchardt, T., Braun, T. (2014). Myostatin regulates energy homeostasis in the heart and prevents heart failure. Circ Res 115(2):296-310. doi: 10.1161 /CIRCRESAHA. 115.304185. PMID:24807786
Biesemann, N., Mendler, L., Kostin, S., Wietelmann, A., Borchardt, T., Braun, T. (2015). Myostatin induces interstitial fibrosis in the heart via TAK1 and p38. Cell Tissue Res. 361(3),779-787. doi: 10.1007/s00441-015-2139-2.PMID:25725788
Bish, L.T., George, I., Maybaum ,S., Yang, J., Chen, J.M., Sweeney, H.L.(2011). Myostatin is elevated in congenital heart disease and after mechanical unloading. PLoS One. 6(9),e23818. doi: 10.1371/journal.pone.0023818. PMID:21931616
Castillero, E., Akashi, H., Wang, C., Najjar, M., Ji, R., Kennel, P.J., Sweeney, H.L., Schulze, P.C., George, I.(2015). Cardiac myostatin upregulation occurs immediately after myocardial ischemia and is involved in skeletal muscle activation of atrophy. Biochem Biophys Res Commun , 457(1),106-111. doi: 10.1016/j.bbrc.2014.12.057. PMID:25528587
Colao, A, Di Somma, C., Casnella, T., Pivonello, R., Vitale, G., Grasso, L.F.S. Lombardi, G., Savastano, S. (2008). Relationship between serum IFGF1 levels, blood pressure and glucose tolerance: an observational, exploratory study in 404 subjects. Eur J Endocrinol, 159: 389-397.
doi: 10.1530/EJE-08-0201. PMID:18603571

Coppini, R., Ferrantini, C., Poggesi, C., Mugelli, A., Olivotto, I.(2016). Molecular targets and novel pharmacological options to prevent myocardial hypertrophic remodeling. G Ital Cardiol (Rome),17(3),189-196. doi: 10.1714/2190.23660.[Article in Italian]
Damatto, R.L., Lima, A.R., Martinez, P.F., Cezar, M.D., Okoshi, K., Okoshi,M,P. (2016).Myocardial myostatin in spontaneously hypertensive rats with heart failure. Int J Cardiol, 215:384-387. doi: 10.1016/j.ijcard.2016.04.101. Epub 2016 Apr 15.PMID:27128567
Deschepper, C.F., Boutin-Ganache, I., Zahabi, A., Jiang, Z.(2002). In search to candidate genes: Interaction between phenotypes and genotypes. Hypertension , 39: 332-336.
PMID:11882568

Diamond, J.A., Philips, R.A. (2005). Hypertensive heart diseases. Hypertension Res, 28,191-202.
PMID:16097361
Díez, J. (2009). Towards a new paradigm about hypertensive heart disease. Med Clin North Am, 93(3), 637-645. doi: 10.1016/j.mcna.2009.02.002. PMID:19427496
Dschietzig, T.B. (2014) Myostatin - From the Mighty Mouse to cardiovascular disease and cachexia. Clin Chim Acta, 433,216-224. doi: 10.1016/j.cca.2014.03.021 PMID:24680839.
Fatjó, F., Fernández-Solà ,J., Lluis, M., Elena ,M., Badía, E., Sacanella, E., Estruch, R.,
Nicolás, J.M. (2005).Myocardial antioxidant status in chronic alcoholism. Alcohol Clin Exp Res ,29 (5), 864-870.
PMID:15897732

Fedak, P.W., Verma, S., Weisel, R.D., Li, R.K. (2005). Cardiac remodelling and failure: from molecules to man (Part I). Cardiovasc Pathol,14(1),1-11. PMID:15710285

Fernández-Solà, J., Fatjó, F., Sacanella, E., Estruch, R., Bosch, X., Urbano-Márquez, A., Nicolás, J.M. (2006). Evidence of apoptosis in alcoholic cardiomyopathy. Hum Pathol 37, 1100-1110.
PMID:16867874
Fernández-Solà, J., Lluis, M., Sacanella, E., Estruch, R., Antúnez, E., Urbano-Márquez, A.(2011). Increased myostatin activity and decreased myocyte proliferation in chronic alcoholic cardiomyopathy. Alcohol Clin Exp Res,35(7),1220-1229. doi: 10.1111/j.1530-02.
Fernández-Solà, J., Borrisser-Pairó, F., Antúnez, E., Tobías, .E. (2015). Myostatin and
insulin-like growth factor-1 in hypertensive heart disease: a prospective study in human heart donors. J Hypertens, 33(4), 851-858; discussion 859. doi: 10.1097/HJH.0000000000000493
Fernández-Solà J. (2015). Cardiovascular risk and benefits of moderate and heavy alcohol consumption. Nature Rev Cardiol, 12(10), 576-587. doi: 10.1038/nrcardio.2015.91. PMID:21463333
Gaussin, V., Depre, C. (2005). Myostatin, the cardiac chalone of insulin-like growth
factor-1. Cardiovasc Res, 68(3),347-349.
PMID:16226233.
George, I., Bish, L.T., Kamalakkannan, G., Petrilli, C.M., Oz, M.C., Naka, Y., Sweeney, H.L., Maybaum ,S. (2010). Myostatin activation in patients with advanced heart failure and after mechanical unloading. Eur J Heart Fail,12,444–453. doi: 10.1093/eurjhf/hfq039. PMID: 20348550
Glembotski, C.C. (2010). Functions for the cardiomyokine, MANF, in cardioprotection,
hypertrophy and heart failure. J Mol Cell Cardiol, 51(4),512-517. doi: 10.1016/j.yjmcc.2010.10.008. PMID:20970425

Gruson, D., Ahnm S,A,, Ketelslegersm J,M,, Rousseaum M,F. (2011). Increased plasma myostatin in heart failure. Eur J Heart Fail,13(7),734-736. doi: 10.1093/eurjhf/hfr024. PMID:21467027
Guzzo-Merello, G., Cobo-Marcos, M., Gallego-Delgado, M., Garcia-Pavia, P. (2014). Alcoholic cardiomyopathy: Pathophysiologic insights. World J Cardiol, 6(8), 771–781.
doi: 10.4330/wjc.v6.i8.771. PMCID: PMC4163706

Heineke, J., Auger-Messier, M., Xu, .J, Sargent, M., Yor,K., Welle, S,, Molkentin, J.D.(2010). Genetic deletion of myostatin from the heart prevents skeletal muscle atrophy in heart failure. Circulation, 121, 419-425. doi: 10.1161/CIRCULATIONAHA.109.882068. PMID:20065166
Hill, J.A., Olson, E.N.(2008). Cardiac Plasticity. N Engl J Med, 358 (13),:1370-1380. DOI: 10.1056/NEJMra072139.
Jin, X., Xia, L., Wang, I., Shi, J., Zheng, Y., Chen, W., Zhang, L., Liu, Z.G., Chen,G.Q.,
Fang, N.Y.(2006). Differential protein expression in hypertrophic heart with and without hypertension in spontaneous hypertensive rats. Proteomics. 6(6):1948-1956. Erratum in: Proteomics. 2006, 6(7):2326. PMID:16485256

Joulia-Ekaza D, Cabello G. (2006).Myostatin regulation of muscle development, molecular basis, natural mutations, physiopathological aspects. Exp Cell Res, 312 (13), 2401-2414.
PMID: 16793037

Kapiloff, M.S., Emter, C.A.(2016) . The cardiac enigma: current conundrums in
heartfailure research. F1000Res, 18(5). pii: F1000 Faculty Rev-72.
doi: 10.12688/f1000research.7278.1. PMID:26918161.
Karlowatz, R.J., Scharhag, J., Rahnenführer, J., Schneider, U., Jakob, E., Kindermann,W., Zang, K.D.(2011). Polymorphisms in the IGF1 signalling pathway including the myostatin gene are associated with left ventricular mass in male athletes. Br J Sports Med, 45(1),36-41. doi: 10.1136/bjsm.2008.050567. PMID:19136503

Kemaladewi, D.U., de Gorter, D.J., Aartsma-Rus, A., van Ommen, G.J., ten Dijke, P., Hoen, P.A., Hoogaars, W.M. (2012). Cell-type specific regulation of myostatin signaling FASEB J, 26(4),1462-1472. doi: 10.1096/fj.11-191189.

Li, N., Wang, C., Jia, L., Du, J. (2014). Heart regeneration, stem cells, and cytokines. Regen Med Res, 2(1), 6. doi: 10.1186/2050-490X-2-6. PMID: 25984334

Li, T., Yang, J., Guo, X., Chen, S., Sun, Y. (2016). Geometrical and functional changes of left heart in adults with prehypertension and hypertension: a cross-sectional study from China.BMC Cardiovasc Disord,6(1),114. PMID:27234840.

Lip, G.Y, Felmeden, D.C., Li-Saw-Hee, F.I., Beevers, D.G. ( 2000). Hypertensive heart
disease: A complex syndrome in hypertensive cardiomyopathy?. Eur Heart J ,21, 1653-1665. PMID:11032692
Loffredo, F.S., Steinhause,r M.L., Jay, S.M., Gannon, J., Pancoast, J.R., Yalamanchi,P., Sinha, M., Dall'Osso, C., Khong, D., Shadrach, J.L., Miller, C.M, Singer, B.S., Stewart, A,, Psychogios, N., Gerszten,R.E., Hartigan, A.J., Kim, M,J., Serwold, T., Wagers, A.J., Lee, R.T. (2013). Growth differentiation factor 11 is a circulating factor that reverses age-related cardiac hypertrophy. Cell, 9, 153(4), 828-839. doi: 10.1016/j.cell.2013.04.015. PMID: 23663781
Lluís, M., Fernández-Solà, J., Castellví-Bel, S., Sacanella, E., Estruch, R., Urbano-Márquez,A. (2011). Evaluation of myocyte proliferation in alcoholic cardiomyopathy: telomerase enzyme activity (TERT) compared with Ki-67 expression. Alcohol Alcohol, 46(5),534-541. doi: 10.1093/alcalc/agr071. PMID:21733836.
McKoy, G., Bicknell, K.A., Patel, K., Brooks, G. (2007).Developmental expression of myostatin in cardiomyocytes and its effect on faetal and neonatal rat cardiomyocyte proliferation. Cardiovasc Res , 74(2), 304-312.
PMID: 17368590.
Morissette, M.R., Cook, S.A., Buranasombati, C., Rosenberg, M.A., Rosenzweig, A. (2009). Myostatin inhibits IGF-I-induced myotube hypertrophy through Akt. Am J Physiol Cell Physiol, 297(5),C1124-3112. doi: 10.1152/ajpcell.00043.2009. PMID:19759331
Nunn, C., Zou, M.X., Sobiesiak, A.J., Roy, A.A., Kirshenbaum, L.A., Chidiac, P. (2010). RGS2 inhibits beta-adrenergic receptor-induced cardiomyocyte hypertrophy. Cell Signal 22(8),1231-1239. doi: 10.1016/j.cellsig.2010.03.015. PMID:20362664
Passino, C., Barison, A., Vergaro, G., Gabutti, A., Borrelli, C., Emdin, M., Clerico, A. (2015) Markers of fibrosis, inflammation, and remodeling pathways in heart failure. Clin Chim Acta, 30,443.:29-38. doi: 10.1016/j.cca.2014.09.006. PMID:25218738
Pedersen, B.K. (2013). Muscle as a secretory organ. Compr Physiol, 3(3),1337-1362. doi: 10.1002/cphy.c120033. PMID:23897689
Planavila, A.,Redondo-Angulo, I., Villarroya, F. (2015). FGF21 and Cardiac Physiopathology. Front Endocrinol (Lausanne), 31(6),133. doi: 10.3389/fendo.2015.00133. PMID: 26379627
Planavila, A., Redondo-Ângulo, I., Ribas, F., Garrabou, G., Casademont, J., Giralt, M., Villarroya, F. (2015). Fibroblast growth factor 21 protects the heart from oxidative stress. Cardiovasc Res, 106(1),19-31. doi: 10.1093/cvr/cvu263. PMID: 25538153
Planavila, A., Redondo, I., Hondares, E., Vinciguerra, M., Munts, C., Iglesias, R.
Gabrielli, L.A., Sitges, M., Giralt, M., van Bilsen, M., Villarroya, F. (2013). Nat
Commun. 4: 2019.
doi: 10.1038/ncomms3019. PMID: 23771152
Rao, R.R., Long, J.Z., White, J.P., Svensson, K.J., Lou, J., Lokurkar, I., Jedrychowski, M.P., Ruas, J.L., Wrann, C.D., Lo, J.C., Camera, D.M., Lachey, J., Gygi, S., Seehra, J., Hawley, J.A., Spiegelman, B.M. (2014). Meteorin-like is a hormone that regulates immune-adipose interactions to increase beige fat thermogenesis. Cell,157(6),1279-1291. doi: 10.1016/j.cell.2014.03.065.
Rodgers, B.D., Interlichia, J.P., Garikipati, D.K., Mamidi, R., Chandra, M., Nelson, O.L., Murry, C.E., Santana, L.F. (2009). Myostatin represses physiological hypertrophy of the heart and excitation-contraction coupling. J Physiol, 587(20),4873-4886. doi: 10.1113/jphysiol.2009.172544. PMID: 19736304
Salzler, R.R., Shah, D., Doré, A., Bauerlein, R., Miloscio, L., Latres, E., Papadopoulos, N.J., Olson, W.C., MacDonald, D., Duan, X. (2016)..Myostatin deficiency but not anti-myostatin blockade induces marked proteomic changes in mouse skeletal muscle. Proteomics May 23. [Epub ahead of print] doi: 10.1002/pmic.201600006.
Sharma, M., McFarlane, C., Kambadur, R., Kukreti, H., Bonala, S., Srinivasan,S.(2015) Myostatin: expanding horizons. IUBMB Life,67(8),589-600. doi: 10.1002/iub.1392. PMID:26305594.
Shyu, K.G., Lu, M.J., Wang, B.W., Sun, H.Y., Chang, H. (2006). Myostatin expression in ventricular myocardium in a rat model of volume-overload heart failure. Eur J Clin Invest,36(10),713-719. PMID:16968467
Takeishi, Y. (2014). Biomarkers in heart failure. Int Heart J, 55(6),474-481.
PMID: 2534136
Tham, Y.K., Bernardo, B.C., Ooi, J.Y., Weeks, K.L., McMullen, J.R. (2015). Pathophysiology of cardiac hypertrophy and heart failure: signalling pathways and novel therapeutic targets. Arch Toxicol,89(9),1401-1438. doi: 10.1007/s00204-015-1477-x. PMID: 25708889
Urbano-Márquez, A., Fernández-Solà, J.(2004) The effects of alcohol on skeletal and cardiac muscle. Muscle &Nerve ,30(6), 689-707. PMID:15490485

Vriz, O., Piccolo, D.M., Cozzutti, E., Milani, I., Gelisio, R., Pegoraro F,Gavaerelli, G,, D'Este, D., Palatini, P. (1998).The effects of alcohol consumption on ambulatory blood pressure and target organs in subjects with borderline to mild hypertension. Am J Hypertens, 11(2),230-234. PMID:9524053

Wang, I., Ma, W., Markovich, R., Chen, J.W., Wang, P.H..(1998) Regulation of cardiomyocyte apototic signaling by insulin-growth-factor 1. Circ Res, 83(5),516-522. PMID: 9734474
Zamora, E., Simó, R., Lupón, J., Galán, A. (2010). Myostatin serum levels in heart failure. Eur J Heart Fail, 12(12),1379. Author reply 1379-1380. doi: 10.1093/eurjhf/hfq190. PMID:21098582
Zheng, S.L., Li, Z.Y., Song, J., Liu, J.M., Miao, C.Y. (2016). Metrnl: a secreted protein with new emerging functions. Acta Pharmacol Sin,37(5),571-579. doi: 10.1038/aps.2016.9.PMID: 27063217